| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Essentially all meaningful efficacy data is animal (rat, pig) studies. Some Phase I human PK/PD safety studies exist but no published human efficacy RCTs. Animal only score applies. |
5 / 25 |
| Sample Size | No human efficacy participants to count. Animal study cohorts are typically small (10-20 animals per group). |
4 / 20 |
| Replication | Animal studies have been replicated across multiple independent research groups for GH pulse amplitude. Consistent animal findings, but not human data. |
10 / 20 |
| Journal Impact Factor | Some publications in Endocrinology (IF ~4.5) and Growth Hormone & IGF Research. Reasonable journal quality for the compound class. |
8 / 15 |
| Funding Independence | Mix of academic and Novo Nordisk-affiliated research (ipamorelin originated in Novo pipeline). Some industry shadow in early research. |
4 / 10 |
| Population Diversity | Animal only — not applicable. |
1 / 5 |
| Researcher h-Index | Some lead researchers have strong profiles. Jens-Otto Clemmensen and Novo Nordisk scientists have solid h-Indexes. Capped at 5. |
3 / 5 |